Previous close | 8.35 |
Open | 8.35 |
Bid | 8.30 x 0 |
Ask | 8.80 x 0 |
Day's range | 8.35 - 8.55 |
52-week range | 6.15 - 13.80 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 31 July 2023 - 04 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -30.77% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NEWPORT BEACH, Calif., May 09, 2023--Evolus, Inc. reports financial results for the first quarter ended March 31, 2023 and provides a business update.
NEWPORT BEACH, Calif., May 09, 2023--Evolus, Inc. announces it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five unique dermal fillers.
NEWPORT BEACH, Calif., May 05, 2023--Evolus, Inc. announces that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023.
It's not a stretch to say that Evolus, Inc.'s ( NASDAQ:EOLS ) price-to-sales (or "P/S") ratio of 3.2x right now seems...
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NEWPORT BEACH, Calif., March 08, 2023--Evolus reports financial results for the fourth quarter and full year ended December 31, 2022 and provides a business update
NEWPORT BEACH, Calif., February 28, 2023--Evolus announces that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida.
NEWPORT BEACH, Calif., February 27, 2023--Evolus commences the commercial launch of Nuceiva® in Germany and Austria, and is now available for direct order and delivery to customers.
NEWPORT BEACH, Calif., February 22, 2023--Evolus announces that it will report its fourth quarter and year end 2022 financial results and provide a business update on Wednesday, March 8, 2023.
NEWPORT BEACH, Calif., February 10, 2023--Evolus issues the following statement.
NEWPORT BEACH, Calif., January 31, 2023--Evolus announces that members of its management team will be participating in the SVB Securities Global Biopharma Conference.
To get a sense of who is truly in control of Evolus, Inc. ( NASDAQ:EOLS ), it is important to understand the ownership...
NEWPORT BEACH, Calif., January 28, 2023--Evolus presents interim data from its Phase II clinical study at the 2023 IMCAS World Congress in Paris.
NEWPORT BEACH, Calif., January 23, 2023--Evolus announces that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva®.
NEWPORT BEACH, Calif., January 23, 2023--Evolus will present interim findings from a Phase 2 study for its "extra-strength" dose of Jeuveau® at the 2023 IMCAS World Congress.
Shares of Evolus (NASDAQ: EOLS) were up by 27.1% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The medical aesthetics company specializes in using neurotoxins as aesthetic therapies. The company said in its announcement that it expected fourth-quarter revenue of $43.6 million, up 26% year over year, and full-year revenue of $148.6 million, up 49% over 2021.
NEWPORT BEACH, Calif., January 18, 2023--Evolus announces its preliminary, unaudited net revenue as of and for the fourth quarter and full-year ended December 31, 2022.
Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine...
NEWPORT BEACH, Calif., December 08, 2022--Evolus announces it has extended the expiration date of the second undrawn tranche under its existing term loan financing facility.
Pipeline Medical, a MedTech marketplace focused on supplying pharmaceuticals and medical supplies to medical professionals around the country, recently announced the addition of Jeuveau® (prabotulinumtoxinA-xvfs) by Evolus, Inc. (NASDAQ: EOLS).
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Evolus ( NASDAQ:EOLS ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.9m (up 27% from 3Q 2021). Net...
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?